RCKT Projected Dividend Yield

Rocket Pharmaceuticals Inc ( NASDAQ : RCKT )

Rocket Pharmaceuticals is a biotechnology company focused on the development of gene therapies for rare and devastating diseases. Co. has various clinical-stage ex vivo lentiviral vector programs. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. In the U.S., Co. has a clinical stage in vivo adeno-associated virus program for Danon disease.

20 YEAR PERFORMANCE RESULTS